Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients

This study has been completed.
Sponsor:
Collaborator:
Cangene Corporation
Information provided by (Responsible Party):
Georgetown University
ClinicalTrials.gov Identifier:
NCT00998426
First received: October 7, 2009
Last updated: March 21, 2014
Last verified: June 2010

October 7, 2009
March 21, 2014
October 2009
September 2011   (final data collection date for primary outcome measure)
change in blood glucose levels prior to HBIG injection and after HBIG injection to determine if there are falsely elevated blood glucose levels after the injection [ Time Frame: immediately pre-injection to 2 hours after injection ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00998426 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients
Evaluation of Blood Glucose Levels for Hepatitis B Immune Globulin (HepaGam B) Administration

HepaGam B Hepatitis B Immune Globulin (HBIG) solution contains 10% maltose, which could possibly interfere with the measurement of glucose levels when using glucose non-specific tests. The purpose of this study is to determine whether use of HepaGam B HBIG shows an increase in glucose levels in the body using non-specific glucose monitoring, as well as specific glucose monitoring. The sponsor believes that this medication will not cause a significant increase in glucose levels in the body when measured by glucose non-specific tests.

Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Hepatitis B
  • Procedure: glucose monitoring before and after HepaGam B administration
    Prior to receiving the dose of HepaGam B HBIG, blood glucose will be monitored in 3 manners. These will include two finger stick tests, one with a glucose-specific monitoring device and one with a glucose non-specific monitoring device; a venous blood glucose level; and a urine glucose test. Patients will receive the HBIG infusion and then immediately after the dose will have the same blood glucose tests repeated (finger sticks, venous glucose and urine glucose). Then at 60 minutes and 120 minutes after the dose is given, patients will again have finger stick tests with the glucose specific and glucose non-specific monitoring devices.
    Other Names:
    • HepaGam B
    • Hepatitis B Immune Globulin
  • Biological: HepaGam B (Hepatitis B Immune Globulin (HBIG))
    Subjects will be given 20,000 IU HepaGam B after the initial blood glucose monitoring, and prior to the post-infusion blood glucose monitoring.
  • Active Comparator: Acute phase
    Study procedures will occur one time between post-op day 1 and post-op day 7. Study procedures to include blood glucose monitoring prior to and after (various time points for 2 hours after) infusion with HBIG.
    Interventions:
    • Procedure: glucose monitoring before and after HepaGam B administration
    • Biological: HepaGam B (Hepatitis B Immune Globulin (HBIG))
  • Active Comparator: chronic phase
    Study procedures will occur one time at least three (3) months post liver transplant. Study procedures to include blood glucose monitoring prior to and after (various time points for 2 hours after) infusion with HBIG.
    Interventions:
    • Procedure: glucose monitoring before and after HepaGam B administration
    • Biological: HepaGam B (Hepatitis B Immune Globulin (HBIG))
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
December 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • written informed consent
  • HBsAG positive candidates for HBV related liver transplant to be placed on HepaGam B therapy for the prevention of HBV recurrence in both the acute phase (immediately post operative) and the long term maintenance phase
  • at least 18 years of age

Exclusion Criteria:

  • unable or unwilling to provide written informed consent
  • concomitant administration of other maltose containing products such as dietary supplements, dietary aids, IVIG, external peritoneal dialysis solution in both arms
  • concomitant administration of corticosteroids in the long term maintenance phase
  • pregnancy, as determined by a pregnancy test administered after consent has been signed
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00998426
2009-337
No
Georgetown University
Georgetown University
Cangene Corporation
Principal Investigator: Kirti Shetty, MD Georgetown University
Georgetown University
June 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP